abril del 2007 Presents results of a pilot study to investigate the safety and efficacy of a new long-lasting injectable formulation of naltrexone to treat of heroin addiction in an outpatient setting.
noviembre del 2009 Discusses the work of NIDA’s Division of Epidemiology, Services and Prevention Research, organized to track drug use and provide empirically based information for researchers and service providers.
Reports findings from a survey that revealed that although substance abuse is prevalent in jails and prisons, many correctional facilities do not offer detoxification services or therapies to aid in maintaining abstinence.
julio del 2012 Dr. J. David Jentsch is the recipient of the 2011 Jacob P. Waletzky Memorial Award for Innovative Research in Drug Addiction and Alcoholism. Dr. Jentsch and colleagues at the University of California, Los Angeles, are studying genetic and neurochemical factors that influence individual differences in inhibitory control.
One of NIDA’s goals is to try to understand the individual differences that contribute to whether or not someone who takes a drug will become addicted to it. Dr. Rutter’s research focuses on three types of differences: Environmental, developmental, and genetic and epigenetic.
Dr. Kevin M. Gray discusses why it’s the perfect time for discovering new evidence-based treatments for marijuana dependence. In an accompanying podcast, he discusses a clinical trial that examines NAC’s potential as a treatment for marijuana dependence among adults.